1y return+52.6%S&P 500 +20.9%
3y return+47.5%S&P 500 +68.5%
5y return+7.3%S&P 500 +74.5%
10y return+112.9%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $213 against $357 in the S&P 500.2
Orbimed Advisors LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| EWTXEdgewise Therapeutics Inc | $630.5M | 12.0% | |
| ELVNEnliven Therapeutics Inc | $343.9M | 6.5% | −14.9% |
| LLYEli Lilly & Co | $309.3M | 5.9% | +8.9% |
| MBXMbx Biosciences Inc | $189.3M | 3.6% | −5.7% |
| Sinovac Biotech LtdCUSIP P8696W104 | $184.5M | 3.5% | |
| Astrazeneca PLCCUSIP G0593M107 | $171.1M | 3.2% | +36.6% |
| GPCRStructure Therapeutics Inc | $118.6M | 2.3% | +49.7% |
| SIONSionna Therapeutics Inc | $112.4M | 2.1% | −27.6% |
| CRVSCorvus Pharmaceuticals Inc | $107.0M | 2.0% | |
| AVBPArrivent Biopharma Inc | $105.2M | 2.0% | |
| GHGuardant Health Inc | $87.6M | 1.7% | +34.1% |
| ARGXArgenx Se | $86.2M | 1.6% | −32.2% |
| MRKMerck & Co Inc | $85.2M | 1.6% | |
| Uniqure NvCUSIP N90064101 | $83.3M | 1.6% | −15.4% |
| PRAXPraxis Precision Medicines I | $77.0M | 1.5% | +33.4% |
| EWEdwards Lifesciences Corp | $75.5M | 1.4% | −32.2% |
| PRLDPrelude Therapeutics Inc | $73.2M | 1.4% | +25.8% |
| ABVXAbivax Sa | $72.8M | 1.4% | +17.4% |
| DYNDyne Therapeutics Inc | $71.9M | 1.4% | +10.9% |
| NTRANatera Inc | $71.1M | 1.4% | |
| CGONCg Oncology Inc | $69.1M | 1.3% | +2.6% |
| UNHUnitedhealth Group Inc | $67.0M | 1.3% | New |
| SPRYArs Pharmaceuticals Inc | $66.4M | 1.3% | |
| Ascendis Pharma A/sCUSIP K08588103 | $65.2M | 1.2% | New |
| HUMHumana Inc | $65.2M | 1.2% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| CRVSCorvus Pharmaceuticals Inc | June 30, 2020 | +449.2% | $107.0M |
| NTRANatera Inc | June 30, 2020 | +444.4% | $71.1M |
| XENEXenon Pharmaceuticals Inc | June 30, 2020 | +381.3% | $53.9M |
| SIONSionna Therapeutics Inc | March 31, 2025 | +320.6% | $112.4M |
| LLYEli Lilly & Co | March 31, 2023 | +249.3% | $309.3M |
| ARGXArgenx Se | March 31, 2022 | +194.2% | $86.2M |
| STTKShattuck Labs Inc | September 30, 2025 | +190.4% | $43.8M |
| ELVNEnliven Therapeutics Inc | March 31, 2023 | +131.7% | $343.9M |
| MBXMbx Biosciences Inc | September 30, 2024 | +112.5% | $189.3M |
| ISRGIntuitive Surgical Inc | June 30, 2020 | +109.4% | $62.8M |
Sold off last quarter
- PFEPfizer Inc was $54.7M
- DHRDanaher Corp Del was $50.4M
- Ascendis Pharma A/sCUSIP 04351P101 was $41.6M
- Esperion Therapeutics Inc NeCUSIP 29664W105 was $29.0M
- BTSGBrightspring Health Svcs Inc was $21.2M
- AMGNAmgen Inc was $14.0M
- ALHCAlignment Healthcare Inc was $13.9M
- REGNRegeneron Pharmaceuticals was $11.4M
- CARLCarlsmed Inc was $11.3M
- GILDGilead Sciences Inc was $8.3M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +15.0% | +14.8% |
| March 31, 2026 | +0.3% | −4.6% |
| December 31, 2025 | +21.7% | +2.4% |
| September 30, 2025 | +8.7% | +7.8% |
| June 30, 2025 | −3.5% | +10.5% |
| March 31, 2025 | −11.6% | −4.6% |
| December 31, 2024 | −11.4% | +2.1% |
| September 30, 2024 | +10.8% | +5.4% |
| June 30, 2024 | −4.3% | +4.0% |
| March 31, 2024 | +17.1% | +10.0% |
| December 31, 2023 | +16.9% | +11.2% |
| September 30, 2023 | −11.9% | −3.6% |
| June 30, 2023 | +7.7% | +8.3% |
| March 31, 2023 | −3.0% | +7.0% |
| December 31, 2022 | +4.0% | +7.1% |
| September 30, 2022 | +7.6% | −5.3% |
| June 30, 2022 | −13.8% | −16.5% |
| March 31, 2022 | −16.4% | −4.9% |
| December 31, 2021 | −6.7% | +10.7% |
| September 30, 2021 | −7.4% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Orbimed Advisors LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1055951&type=13F-HR&dateb=&owner=include&count=40CIK 1055951
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1055951/000117266126003740/Filed August 14, 2026 · accession 0001172661-26-003740